Jan H.M. Schellens

Research interests

Publications

• Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket study

  Annals of Oncology · 2022 · 10.1016/j.annonc.2021.12.014

• Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial

  The Lancet Oncology · 2020 · 10.1016/s1470-2045(20)30321-1

• Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors

  Annals of Oncology · 2019 · 10.1093/annonc/mdy551

• Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1908075

• Pembrolizumab After Two or More Lines of Previous Therapy in Patients With Recurrent or Metastatic SCLC: Results From the KEYNOTE-028 and KEYNOTE-158 Studies

  Journal of Thoracic Oncology · 2019 · 10.1016/j.jtho.2019.12.109

• Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAF V600E-Mutant Colorectal Cancer

  Cancer Discovery · 2018 · https://doi.org/10.1158/2159-8290.cd-17-1226

• DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

  The Lancet Oncology · 2018 · 10.1016/s1470-2045(18)30686-7

• Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study

  Journal of Clinical Oncology · 2018 · 10.1200/jco.2017.72.7107

• Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2017.73.6785

• Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

  Journal of Clinical Oncology · 2017 · 10.1200/jco.2016.67.2048

• Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

  Clinical Pharmacology & Therapeutics · 2017 · 10.1002/cpt.911

• Phase II Study of WEE1 Inhibitor AZD1775 Plus Carboplatin in Patients With TP53-Mutated Ovarian Cancer Refractory or Resistant to First-Line Therapy Within 3 Months

  Journal of Clinical Oncology · 2016 · 10.1200/jco.2016.67.5942

• Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis

  Journal of Clinical Oncology · 2015 · 10.1200/jco.2015.63.1325

• Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)00286-7

• Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy

  Investigational New Drugs · 2014 · 10.1007/s10637-014-0179-1

• Approaching tumour therapy beyond platinum drugs

  Journal of Inorganic Biochemistry · 2011 · 10.1016/j.jinorgbio.2011.09.030

• Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies

  Clinical Pharmacokinetics · 2010 · 10.2165/11531280-000000000-00000

• Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval

  Journal of Clinical Oncology · 2010 · https://doi.org/10.1200/jco.2009.26.9589

• Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers

  New England Journal of Medicine · 2009 · https://doi.org/10.1056/nejmoa0900212

• Photodynamic Therapy in Oncology

  The Oncologist · 2006 · 10.1634/theoncologist.11-9-1034

• A Phase I and Pharmacological Study with Imidazolium- trans- DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent

  Clinical Cancer Research · 2004 · 10.1158/1078-0432.ccr-03-0746

• An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons

  Toxicology and Applied Pharmacology · 2003 · 10.1016/s0041-008x(03)00128-5

• Increased Oral Bioavailability of Topotecan in Combination With the Breast Cancer Resistance Protein and P-Glycoprotein Inhibitor GF120918

  Journal of Clinical Oncology · 2002 · 10.1200/jco.2002.12.116

• Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C.

  PubMed · 2002

• Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.

  PubMed · 2001

Current projects

No projects listed.